The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis

Table 4

Subgroup analyses of risk of miscarriage according to eligibility criteria and vaginal progesterone dose.

Subgroups	Studies,	Number of patients (%)		OR (95% CI)	value	Heterogeneity ()
		Progesterone	Control
Eligibility criteria
Threatened abortion within 12 completed weeks of gestation	4	22/202 (10.9)	35/182 (19.2)	0.47 (0.26–0.86)	0.01	0%
Threatened abortion before 20 weeks of gestation	3	30/197 (15.2)	47/196 (24.0)	0.60 (0.27–1.31)	0.20	53%
Vaginal progesterone dose
High	2	18/101 (17.8)	20/101 (19.8)	0.85 (0.35–2.05)	0.72	30%
Low	2	4/42 (9.5)	9/42 (21.4)	0.39 (0.11–1.37)	0.14	0%

-dose use of vaginal progesterone included studies that administered 400 mg per day for 1 week or until bleeding stopped within less than 1 week. -dose use of vaginal progesterone included studies using a dose lower than the reported high dose.